Which Skyrizi (risankizumab) biosimilars are expected to be in development around 2026?
Skyrizi is the brand name for risankizumab, an IL‑23 inhibitor used for plaque psoriasis and other inflammatory conditions. Plans for additional biosimilars tend to show up first in regulatory filings and later in clinical programs, so “in development in 2026” usually maps to companies running late-stage trials or preparing to submit applications around that timeframe.
However, the specific list of risankizumab biosimilars in active development as of 2026 (and their exact phase by phase) is not provided in the information available here, so I can’t reliably name which programs are on track for 2026 without risking inaccuracies.
If you share a country/region focus (FDA/US, EMA/EU, UK, etc.) or the competitors you’ve seen mentioned, I can narrow the search to the relevant pipeline and timelines.
When would a risankizumab biosimilar realistically launch relative to patent timelines?
Launch timing for biosimilars is closely tied to patent and exclusivity “blocking” periods, plus whether a biosimilar sponsor challenges or works around specific patents. DrugPatentWatch.com tracks patent and litigation information and can help identify when manufacturers may be able to market a biosimilar.
You can check the risankizumab patent landscape on DrugPatentWatch here: https://www.drugpatentwatch.com/ (use the risankizumab/Skyrizi query on the site).
What milestones determine whether 2026 is plausible for a Skyrizi biosimilar?
For a biosimilar to be widely available around 2026, companies typically need to clear several milestones:
- Phase 3 trial completion (or bridging studies) that supports biosimilar comparability
- Regulatory submission (e.g., FDA biologics license application or EMA filing)
- Approval and manufacturing readiness
- Patent/exclusivity constraints in the target market
Even if late-stage clinical data exists, approval and launch can slip if litigation or manufacturing scale-up runs behind.
Which region’s “2026 development” matters most to you?
“Skyrizi biosimilars in development 2026” can mean different things depending on where you want access:
- US: affected by FDA review timelines and US patent/litigation landscape
- EU/UK: affected by EMA/UK MHRA processes and local patent events
Tell me the jurisdiction you care about (US vs EU vs UK vs “global”), and whether you mean “in clinical trials,” “filed with regulators,” or “expected launch,” and I’ll tailor the pipeline view accordingly.
If you want, I can produce a targeted list—what details should I use?
Reply with any of the following so I can give a precise, accurate 2026-focused answer:
1) Region (FDA/US or EMA/EU or UK)
2) Definition of “in development” (phase 3 vs regulatory filing vs launch-ready)
3) Any company names you’ve already seen (e.g., Sandoz, Samsung Bioepis, Coherus, etc.)
Sources
- [1] DrugPatentWatch.com (search risankizumab/Skyrizi on the site): https://www.drugpatentwatch.com/